UBS Asset Management Americas Inc. boosted its position in Opko Health Inc. (NYSE:OPK) by 5.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 248,477 shares of the company’s stock after buying an additional 13,699 shares during the period. UBS Asset Management Americas Inc.’s holdings in Opko Health were worth $2,321,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the company. Financial Architects Inc increased its position in Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock valued at $102,000 after buying an additional 1,940 shares during the last quarter. First Citizens Bank & Trust Co. bought a new position in Opko Health during the second quarter valued at about $103,000. Janney Montgomery Scott LLC increased its position in Opko Health by 23.0% in the second quarter. Janney Montgomery Scott LLC now owns 13,284 shares of the company’s stock valued at $134,000 after buying an additional 2,485 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Opko Health during the first quarter valued at about $141,000. Finally, Capstone Asset Management Co. increased its position in Opko Health by 16.4% in the second quarter. Capstone Asset Management Co. now owns 15,696 shares of the company’s stock valued at $147,000 after buying an additional 2,210 shares during the last quarter.
Opko Health Inc. (NYSE:OPK) traded down 4.99% during midday trading on Friday, reaching $9.91. 8,360,437 shares of the company traded hands. Opko Health Inc. has a 12 month low of $7.12 and a 12 month high of $11.85. The firm has a market capitalization of $5.45 billion and a PE ratio of 41.46. The company’s 50-day moving average price is $10.06 and its 200 day moving average price is $10.12.
Opko Health (NYSE:OPK) last issued its earnings results on Monday, August 8th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.05. The company had revenue of $357.10 million for the quarter, compared to analysts’ expectations of $324.11 million. Opko Health’s revenue for the quarter was up 742.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.09) earnings per share. On average, equities analysts anticipate that Opko Health Inc. will post ($0.05) earnings per share for the current year.
OPK has been the subject of a number of recent research reports. Oppenheimer Holdings Inc. reiterated an “outperform” rating on shares of Opko Health in a research report on Saturday, June 25th. JPMorgan Chase & Co. set a $14.00 target price on shares of Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. Deutsche Bank AG reduced their target price on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating for the company in a research report on Thursday, June 16th. Jefferies Group reiterated a “hold” rating and issued a $10.00 target price (down from $11.00) on shares of Opko Health in a research report on Friday, June 17th. Finally, Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Opko Health currently has a consensus rating of “Buy” and a consensus target price of $13.20.
In related news, CEO Phillip Md Et Al Frost bought 10,000 shares of the firm’s stock in a transaction on Monday, July 11th. The shares were bought at an average cost of $9.82 per share, for a total transaction of $98,200.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $30,137,098.82. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NYSE:OPK).
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.